chronic lymphocytic leukemia/small lymphocytic lymphoma (Cancer)
Information
- Disease name
- chronic lymphocytic leukemia/small lymphocytic lymphoma
- Disease ID
- DOID:6354
- Description
- "A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes." [url:http\://www.cancer.gov/dictionary?CdrID=641291, url:https\://lymphoma.org/aboutlymphoma/cll/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04657094 | Active, not recruiting | Phase 2 | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | March 16, 2021 | December 30, 2024 |
| NCT02268851 | Completed | Phase 1 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | November 2014 | August 2023 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT03041636 | Completed | Phase 2 | Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | March 8, 2017 | April 29, 2020 |
| NCT03128359 | Completed | Phase 2 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | May 30, 2017 | September 15, 2021 |
| NCT00090090 | Completed | Phase 2 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | April 2004 | October 2006 |
| NCT04748185 | Completed | Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies | January 28, 2021 | July 13, 2022 | |
| NCT05007860 | Completed | Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia | July 16, 2020 | June 30, 2023 | |
| NCT05923502 | Not yet recruiting | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | October 20, 2023 | November 30, 2027 | |
| NCT05876923 | Recruiting | N/A | The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients | March 13, 2023 | April 2028 |
| NCT04116437 | Recruiting | Phase 2 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | October 15, 2019 | October 2025 |
| NCT05665530 | Recruiting | Phase 1 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies | September 12, 2023 | April 2025 |
| NCT04458610 | Recruiting | Phase 2 | Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | May 26, 2020 | May 26, 2026 |
| NCT05294731 | Recruiting | Phase 1/Phase 2 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | March 24, 2022 | March 2027 |
| NCT05322733 | Recruiting | Phase 2 | Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | April 15, 2022 | November 5, 2025 |
| NCT05643235 | Recruiting | N/A | Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors | January 1, 2023 | December 1, 2030 |
| NCT05003141 | Unknown status | Phase 1 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | November 15, 2021 | January 2024 |
| NCT04665115 | Withdrawn | Phase 2 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | November 23, 2020 | July 22, 2022 |
- Disase is a (Disease Ontology)
- DOID:1040
- Cross Reference ID (Disease Ontology)
- ICDO:9823/3
- Cross Reference ID (Disease Ontology)
- NCI:C27911
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:399607007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1302547
- Exact Synonym (Disease Ontology)
- B-cell lymphocytic leukemia/small lymphocytic lymphoma
- Exact Synonym (Disease Ontology)
- CLL/SLL